OmniSenseClinical
Aster Medcity · Kochi
Dr. Rajesh Menon CICU · Cardiologist · D001
RM

Your patients

11 patients · CICU + Cardiac Surgical Step-Down

Ms. Fatima Rahman, 28F · CICU 1 · Myocarditis
Mr. Sasi Pillai, 62M · CICU 12 · Post-PCI STEMI
Mrs. Latha Nair, 58F · CICU 8 · Decomp HFrEF
Mr. Hari Krishnan, 71M · CICU 3 · NSTEMI
Mr. Venu Rao, 68M · SD-4 · Pre-op CABG
Mr. K. George, 64M · CICU 5
Mr. Sasi Pillai AKI rising Drug-safety flag
62M · CICU bed 12 · MRN AST-2026-04-0998 · Admitted Tue 09 Apr 13:42 · Day 2 post-PCI
Summary
Journey
Body
⚠
Active concern · cardio ↔ nephro
Creatinine bumped 0.9 → 1.4 overnight (KDIGO Stage 1 AKI). Most likely contrast nephropathy from yesterday’s PCI — superimposed on chronic ACE-i + metformin exposure. The kidneys are the system at risk this morning, the heart is recovering.
Coronary tree · LAD post-PCI day 2 · DES 3.0 × 28 mm
RV LV Aorta L Main LAD DES 3.0 × 28 mm LCx patent RCA patent PDA Drug-eluting stent
LAD post-stent (DES 3.0×28 mm) · door-to-balloon 55 min · trop trending down 2.8 → 1.4 ng/mL. Wall motion recovering on the morning echo, EF 42 % (was 38 %). LCx and RCA patent.
Renal tract · coronal section · bilateral AKI (KDIGO 1)
Aorta IVC pelvis Renal a. ureter cortex LEFT KIDNEY eGFR 52 → 42 pelvis Renal a. RIGHT KIDNEY eGFR 52 → 42 CORTEX (amber) site of contrast-induced tubular injury SYMMETRIC PATTERN no obstructive features on bedside US
Bilateral cortical insult pattern · eGFR 52 → 42 overnight (baseline ~60) · bedside US shows normal-sized kidneys, no hydronephrosis · consistent with contrast-induced nephropathy after yesterday’s PCI.
Active medications · safety review
Hold? Metformin 1g BD eGFR 42 · below 45 cut-off · flagged for hold
Hold? Ramipril 5 mg OD ACE-i in evolving AKI · consider 24h pause
Continue Aspirin 75 mg + Ticagrelor 90 mg BD DAPT post-DES · mandatory 12 months
Continue Atorvastatin 80 mg OD High-intensity statin post-MI
Continue Bisoprolol 2.5 mg OD HR 78 SR · well tolerated
Reference only. Clinical decision rests with the treating physician. Drug-safety flags are evidence-cited and audited. Sources: KDIGO AKI 2024, Aster formulary v8.2.